Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

WSD0922

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Wayshine Biopharm

Drug class:

EGFR inhibitor, EGFRvIII inhibitor

Related drugs:

‹

Undisclosed EGFRvIII-targeted alpha therapy (1)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

Undisclosed EGFRvIII-targeted alpha therapy (1)

›

EGFRvIII mutation

Sensitive: C3 – Early Trials

Sensitive: C3 – Early Trials